Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 943

1.

Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease.

Hijazi S, Heistek TS, Scheltens P, Neumann U, Shimshek DR, Mansvelder HD, Smit AB, van Kesteren RE.

Mol Psychiatry. 2019 Aug 20. doi: 10.1038/s41380-019-0483-4. [Epub ahead of print]

PMID:
31431685
2.

Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials.

Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC.

J Neurol. 2019 Aug 14. doi: 10.1007/s00415-019-09493-9. [Epub ahead of print] Review.

PMID:
31414194
3.

Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60-102 years.

Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, Visser PJ.

J Gerontol A Biol Sci Med Sci. 2019 Aug 14. pii: glz180. doi: 10.1093/gerona/glz180. [Epub ahead of print]

PMID:
31411322
4.

Added value of amyloid PET in individualized risk predictions for MCI patients.

van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, Berkhof J, van der Flier WM.

Alzheimers Dement (Amst). 2019 Jul 29;11:529-537. doi: 10.1016/j.dadm.2019.04.011. eCollection 2019 Dec.

5.

Clinician-patient communication during the diagnostic workup: The ABIDE project.

Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, Schuur J, Wind HA, Blaauw MSJ, Kragt JJ, Roks G, Boelaarts L, Schipper AC, Schooneboom N, Scheltens P, van der Flier WM, Smets EMA.

Alzheimers Dement (Amst). 2019 Jul 29;11:520-528. doi: 10.1016/j.dadm.2019.06.001. eCollection 2019 Dec.

6.

Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study.

Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL.

J Alzheimers Dis. 2019 Jul 22. doi: 10.3233/JAD-190344. [Epub ahead of print]

PMID:
31356209
7.

Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease.

den Haan J, Csinscik L, Parker T, Paterson RW, Slattery CF, Foulkes A, Bouwman FH, Verbraak FD, Scheltens P, Peto T, Lengyel I, Schott JM, Crutch SJ, Shakespeare TJ, Yong KXX.

Alzheimers Res Ther. 2019 Jul 18;11(1):62. doi: 10.1186/s13195-019-0516-x.

8.

Cognitive and functional progression of dementia in two longitudinal studies.

Wang Y, Haaksma ML, Ramakers IHGB, Verhey FRJ, van de Flier WM, Scheltens P, van Maurik I, Olde Rikkert MGM, Leoutsakos JS, Melis RJF.

Int J Geriatr Psychiatry. 2019 Jul 18. doi: 10.1002/gps.5175. [Epub ahead of print]

PMID:
31318090
9.

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease.

van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM.

JMIR Form Res. 2019 Jul 8;3(3):e13417. doi: 10.2196/13417.

10.

Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks.

Boelaarts L, Meyer SRA, Scheltens P, de Jonghe JFM.

Dement Geriatr Cogn Dis Extra. 2019 Jun 18;9(2):207-216. doi: 10.1159/000499836. eCollection 2019 May-Aug.

11.

Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum.

Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM.

Alzheimers Res Ther. 2019 Jul 4;11(1):60. doi: 10.1186/s13195-019-0510-3.

12.

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.

Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative.

J Neurol. 2019 Jul 2. doi: 10.1007/s00415-019-09441-7. [Epub ahead of print]

PMID:
31267207
13.

Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.

van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2019 Jul 23;93(4):e334-e346. doi: 10.1212/WNL.0000000000007821. Epub 2019 Jul 2.

PMID:
31266904
14.

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease.

Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH.

Alzheimers Dement (Amst). 2019 Jun 18;11:463-471. doi: 10.1016/j.dadm.2019.05.002. eCollection 2019 Dec.

15.

Cerebrospinal fluid collection: An informative animation video for patients and caregivers.

Babapour Mofrad R, Visser LNC, Fruijtier AD, Scheltens P, Smets EEMA, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2019 Jun 12;11:435-438. doi: 10.1016/j.dadm.2019.04.005. eCollection 2019 Dec.

16.

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?

Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH.

Alzheimers Dement (Amst). 2019 May 10;11:383-391. doi: 10.1016/j.dadm.2019.03.006. eCollection 2019 Dec.

17.

White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study.

Legdeur N, Visser PJ, Woodworth DC, Muller M, Fletcher E, Maillard P, Scheltens P, DeCarli C, Kawas CH, Corrada MM.

J Am Geriatr Soc. 2019 Jun 6. doi: 10.1111/jgs.15990. [Epub ahead of print]

PMID:
31169919
18.

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups.

Alzheimers Dement. 2019 Jul;15(7):888-898. doi: 10.1016/j.jalz.2019.04.001. Epub 2019 Jun 1.

PMID:
31164314
19.

Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease.

Pelkmans W, Dicks E, Barkhof F, Vrenken H, Scheltens P, van der Flier WM, Tijms BM.

Hum Brain Mapp. 2019 Sep;40(13):3900-3909. doi: 10.1002/hbm.24638. Epub 2019 Jun 3.

PMID:
31157938
20.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27.

21.

Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project.

Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE.

Nutrients. 2019 May 23;11(5). pii: E1161. doi: 10.3390/nu11051161.

22.

Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study.

Eikelboom WS, Singleton E, van den Berg E, Coesmans M, Mattace Raso F, van Bruchem RL, Goudzwaard JA, de Jong FJ, Koopmanschap M, den Heijer T, Driesen JJM, Vroegindeweij LJHM, Thomeer EC, Hoogers SE, Dijkstra AA, Zuidema SU, Pijnenburg YAL, Scheltens P, van Swieten JC, Ossenkoppele R, Papma JM.

Alzheimers Res Ther. 2019 May 24;11(1):48. doi: 10.1186/s13195-019-0503-2.

23.

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.

Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G.

Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w.

24.

Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort.

Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM.

Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5.

25.

Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project.

Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM.

Nutrients. 2019 May 11;11(5). pii: E1057. doi: 10.3390/nu11051057.

26.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

27.

High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline.

Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM.

Neuropsychologia. 2019 Aug;131:184-192. doi: 10.1016/j.neuropsychologia.2019.05.006. Epub 2019 May 7.

28.

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.

Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2019 Jun 4;92(23):e2699-e2705. doi: 10.1212/WNL.0000000000007609. Epub 2019 May 8.

29.

Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

30.

Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders.

Fuermaier ABM, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O.

J Alzheimers Dis. 2019;69(4):1019-1030. doi: 10.3233/JAD-181095.

PMID:
31045516
31.

ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.

Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM, Veerhuis R.

Neurobiol Aging. 2019 Jul;79:101-109. doi: 10.1016/j.neurobiolaging.2019.02.017. Epub 2019 Mar 1.

PMID:
31029938
32.

Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.

Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, Windhorst AD, Wolters EE, Yaqub M, Prins ND, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BNM.

Neurobiol Aging. 2019 Jul;79:50-58. doi: 10.1016/j.neurobiolaging.2019.02.020. Epub 2019 Mar 8.

33.

Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study

Leeuwis AE, Weaver NA, Biesbroek JM, Exalto LG, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, van der Flier WM, Biessels GJ; TRACE-VCI study group.

J Psychiatry Neurosci. 2019 Jul 1;44(4):E1-E10.

34.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

35.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
36.

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.

Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, Tijms BM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2019;22:101786. doi: 10.1016/j.nicl.2019.101786. Epub 2019 Mar 19.

37.

How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study.

Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Leeuwis AE, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ; behalf of the TRACE-VCI study group.

J Alzheimers Dis. 2019;68(3):1273-1286. doi: 10.3233/JAD-180696.

PMID:
30909212
38.

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.

Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K, Frisoni G, Blin O, Richardson JC, Bordet R, Tsolaki M, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Lleó A, Johannsen P, Freund-Levi Y, Frölich L, Vandenberghe R, Westwood S, Dobricic V, Barkhof F, Legido-Quigley C, Bertram L, Lovestone S, Streffer J, Andreasson U, Blennow K, Zetterberg H, Visser PJ.

Alzheimers Dement. 2019 May;15(5):644-654. doi: 10.1016/j.jalz.2019.01.004. Epub 2019 Mar 8.

PMID:
30853464
39.

Automatically computed rating scales from MRI for patients with cognitive disorders.

Koikkalainen JR, Rhodius-Meester HFM, Frederiksen KS, Bruun M, Hasselbalch SG, Baroni M, Mecocci P, Vanninen R, Remes A, Soininen H, van Gils M, van der Flier WM, Scheltens P, Barkhof F, Erkinjuntti T, Lötjönen JMP; Alzheimer’s Disease Neuroimaging Initiative.

Eur Radiol. 2019 Sep;29(9):4937-4947. doi: 10.1007/s00330-019-06067-1. Epub 2019 Feb 22.

PMID:
30796570
40.

Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study.

Konijnenberg E, den Braber A, Ten Kate M, Tomassen J, Mulder SD, Yaqub M, Teunissen CE, Lammertsma AA, van Berckel BNM, Scheltens P, Boomsma DI, Visser PJ.

Neurobiol Aging. 2019 May;77:58-65. doi: 10.1016/j.neurobiolaging.2019.01.006. Epub 2019 Jan 21.

41.

The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.

Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ; TRACE-VCI study group.

J Alzheimers Dis. 2019;68(1):311-322. doi: 10.3233/JAD-180914.

PMID:
30775988
42.

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project.

Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, Sikkes SAM, Yaqub M, Dols A, Lammertsma AA, Scheltens P, Ossenkoppele R, van Berckel BNM, van der Flier WM.

Front Aging Neurosci. 2019 Jan 25;11:7. doi: 10.3389/fnagi.2019.00007. eCollection 2019.

43.

"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".

Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R.

Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. No abstract available.

PMID:
30642435
44.

Computer-assisted prediction of clinical progression in the earliest stages of AD.

Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, Slot RER, Verfaillie SCJ, Scheltens P, Tijms BM, Lötjönen J, van der Flier WM.

Alzheimers Dement (Amst). 2018 Oct 8;10:726-736. doi: 10.1016/j.dadm.2018.09.001. eCollection 2018.

45.

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result.

Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, Galimberti D, Parnetti L, Lleó A, Baker S, Narayan VA, van der Flier WM, Scheltens P, Teunissen CE, Visser PJ, Lovestone S.

Front Aging Neurosci. 2018 Dec 11;10:409. doi: 10.3389/fnagi.2018.00409. eCollection 2018.

46.

The plasma peptides of ovarian cancer.

Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen CE, Diamandis EP, Michael Siu KW, Marshall JG.

Clin Proteomics. 2018 Dec 21;15:41. doi: 10.1186/s12014-018-9215-z. eCollection 2018.

47.

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.

den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, Bergen AAB, Bouwman FH, Hoozemans JJ.

Acta Neuropathol Commun. 2018 Dec 28;6(1):147. doi: 10.1186/s40478-018-0650-x.

48.

Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study.

Beker N, Sikkes SAM, Hulsman M, Schmand B, Scheltens P, Holstege H.

J Am Geriatr Soc. 2019 Apr;67(4):759-767. doi: 10.1111/jgs.15729. Epub 2018 Dec 27.

PMID:
30592018
49.

Parametric methods for [18F]flortaucipir PET.

Golla SS, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, Schwarte L, Mintun MA, Devous MD Sr, Schuit RC, Windhorst AD, Lammertsma AA, Yaqub M, van Berckel BN, Boellaard R.

J Cereb Blood Flow Metab. 2018 Dec 20:271678X18820765. doi: 10.1177/0271678X18820765. [Epub ahead of print]

PMID:
30569813
50.

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease.

Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE.

Alzheimers Dement (Amst). 2018 Nov 12;11:1-9. doi: 10.1016/j.dadm.2018.10.004. eCollection 2019 Dec.

Supplemental Content

Loading ...
Support Center